Eli Lilly to acquire AtaiBeckley for $2.8B to target treatment-resistant depression
What's the deal? Eli LillyDealroom has a profile for this one. Try Dealroom → has agreed to acquire clinical-stage biopharmaceutical company AtaiBeckley in a cash deal valued at roughly $2.8 billion. Shareholders will get $6.75 per share upfront, plus up to $2.50 per share tied to development and regulatory milestones. The deal was announced on July 16, 2026.
What's the endgame? The acquisition expands Lilly's neuroscience pipeline into rapid-acting neuroplastogens — therapies designed to restore the brain's ability to form and strengthen connections. That marks a distinct approach from conventional antidepressants, which mainly target neurotransmitter levels.
What are the assets? AtaiBeckley's lead program, BPL-003, is a synthetic form of 5-MeO-DMT delivered intranasally for treatment-resistant depression, which affects millions in the US. In a Phase 2b study, it showed rapid, durable symptom reductions after an in-clinic visit of about two hours, with benefits lasting months. The drug has US Food and Drug Administration Breakthrough Therapy Designation and has started Phase 3 activities. A second program, VLS-01, a buccal film formulation of DMT, is in an ongoing Phase 2b study.
How the payout works: The upfront cash represents about $2.8 billion in equity value. The Contingent Value Right adds up to $2.50 per share: $1.00 on initiating a Phase 3 trial of VLS-01 before the fourth anniversary of closing; $0.50 on US approval and DEA rescheduling of BPL-003 before the fifth anniversary; and $1.00 on US approval and DEA rescheduling of VLS-01 before the seventh.
What they're saying: "Millions of people are still searching for relief and desperately need a therapy that works," said Carole Ho, executive vice president and president of Lilly Neuroscience. AtaiBeckley co-founder and chief executive officer Srinivas RaoDealroom has a profile for this one. Try Dealroom → said the company aims to show "that psychiatric illness is treatable at its biological root, not just its symptoms."
What could go wrong? Much of the deal's value hinges on milestones that may not be met. The CVR payments depend on Phase 3 progress and, critically, DEA rescheduling of two psychedelic-derived compounds — regulatory hurdles that fall outside the companies' control.
The signal: Lilly's bet moves a major pharmaceutical player deeper into psychedelic-derived psychiatry, an area long confined to smaller clinical-stage firms. By backing mechanisms aimed at the biology of depression rather than its symptoms, the deal signals growing mainstream confidence in neuroplastogens as a treatment frontier.
Read more: PR Newswire
